The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10316/11809 https://doi.org/10.1358/mf.2009.31.2.1338414 |
Resumo: | The choice of appropriate animal models for the initial in vivo testing of potential anticonvulsant compounds is one of the most important steps in the successful search for new antiepileptic drugs. The purpose of this paper is to describe the most important aspects to take into account when performing the maximal electroshock seizure (MES) test in the routine laboratory screening of new antiepileptics: the conventional and threshold MES test experimental procedures, the factors affecting experimental data (laboratory conditions, administration vehicles and drug formulations, time after drug administration, and stimulus duration and site of stimulation) and the assessment of anticonvulsant activity are discussed. |
id |
RCAP_d7ce560a8ff63cc243f90055d5d9a262 |
---|---|
oai_identifier_str |
oai:estudogeral.uc.pt:10316/11809 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugsAntiepilépticosTestes in vivoModelos de convulsõesElectrochoqueThe choice of appropriate animal models for the initial in vivo testing of potential anticonvulsant compounds is one of the most important steps in the successful search for new antiepileptic drugs. The purpose of this paper is to describe the most important aspects to take into account when performing the maximal electroshock seizure (MES) test in the routine laboratory screening of new antiepileptics: the conventional and threshold MES test experimental procedures, the factors affecting experimental data (laboratory conditions, administration vehicles and drug formulations, time after drug administration, and stimulus duration and site of stimulation) and the assessment of anticonvulsant activity are discussed.3910-3178-31BA | MARIA MARGARIDA COUTINHO DE SEABRA CASTEL-BRANCO CAETANOinfo:eu-repo/semantics/publishedVersionProus Scientific2009-03info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/11809http://hdl.handle.net/10316/11809https://doi.org/10.1358/mf.2009.31.2.1338414engMethods Find Exp Clin Pharmacol. 31:1 (2009) 101-106.cv-prod-143882Castel-Branco, M. M.Alves, G. L.Figueiredo, I. V.Falcão, AmílcarCaramona, M. M.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-08-29T14:20:37Zoai:estudogeral.uc.pt:10316/11809Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:47:28.414994Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs |
title |
The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs |
spellingShingle |
The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs Castel-Branco, M. M. Antiepilépticos Testes in vivo Modelos de convulsões Electrochoque |
title_short |
The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs |
title_full |
The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs |
title_fullStr |
The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs |
title_full_unstemmed |
The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs |
title_sort |
The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs |
author |
Castel-Branco, M. M. |
author_facet |
Castel-Branco, M. M. Alves, G. L. Figueiredo, I. V. Falcão, Amílcar Caramona, M. M. |
author_role |
author |
author2 |
Alves, G. L. Figueiredo, I. V. Falcão, Amílcar Caramona, M. M. |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Castel-Branco, M. M. Alves, G. L. Figueiredo, I. V. Falcão, Amílcar Caramona, M. M. |
dc.subject.por.fl_str_mv |
Antiepilépticos Testes in vivo Modelos de convulsões Electrochoque |
topic |
Antiepilépticos Testes in vivo Modelos de convulsões Electrochoque |
description |
The choice of appropriate animal models for the initial in vivo testing of potential anticonvulsant compounds is one of the most important steps in the successful search for new antiepileptic drugs. The purpose of this paper is to describe the most important aspects to take into account when performing the maximal electroshock seizure (MES) test in the routine laboratory screening of new antiepileptics: the conventional and threshold MES test experimental procedures, the factors affecting experimental data (laboratory conditions, administration vehicles and drug formulations, time after drug administration, and stimulus duration and site of stimulation) and the assessment of anticonvulsant activity are discussed. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009-03 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10316/11809 http://hdl.handle.net/10316/11809 https://doi.org/10.1358/mf.2009.31.2.1338414 |
url |
http://hdl.handle.net/10316/11809 https://doi.org/10.1358/mf.2009.31.2.1338414 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Methods Find Exp Clin Pharmacol. 31:1 (2009) 101-106. cv-prod-143882 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Prous Scientific |
publisher.none.fl_str_mv |
Prous Scientific |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133752130011136 |